Avant Diagnostics (OTCMKTS:AVDX) and Fulgent Genetics (NASDAQ:FLGT) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, risk, institutional ownership, valuation, dividends and earnings.
Volatility & Risk
Avant Diagnostics has a beta of 10.7, suggesting that its share price is 970% more volatile than the S&P 500. Comparatively, Fulgent Genetics has a beta of 1.34, suggesting that its share price is 34% more volatile than the S&P 500.
This is a summary of recent recommendations for Avant Diagnostics and Fulgent Genetics, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Fulgent Genetics has a consensus price target of $5.05, indicating a potential downside of 24.29%. Given Fulgent Genetics’ higher probable upside, analysts plainly believe Fulgent Genetics is more favorable than Avant Diagnostics.
This table compares Avant Diagnostics and Fulgent Genetics’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Institutional and Insider Ownership
0.0% of Avant Diagnostics shares are held by institutional investors. Comparatively, 6.6% of Fulgent Genetics shares are held by institutional investors. 38.0% of Avant Diagnostics shares are held by insiders. Comparatively, 58.8% of Fulgent Genetics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Earnings & Valuation
This table compares Avant Diagnostics and Fulgent Genetics’ gross revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Avant Diagnostics||$250,000.00||8.09||-$2.37 million||N/A||N/A|
|Fulgent Genetics||$21.36 million||5.71||-$5.61 million||($0.19)||-35.11|
Avant Diagnostics has higher earnings, but lower revenue than Fulgent Genetics.
Fulgent Genetics beats Avant Diagnostics on 7 of the 11 factors compared between the two stocks.
About Avant Diagnostics
Avant Diagnostics, Inc., a molecular diagnostic company, focuses on the development and commercialization of proprietary diagnostic tests that provide information for physicians and patients in the areas of cancers. It offers OvaDx, a noninvasive proteomics diagnostic screening test for the early detection of ovarian cancer. The company was founded in 2009 and is based in Washington, District of Columbia.
About Fulgent Genetics
Fulgent Genetics, Inc., together with its subsidiaries, provides genetic testing services to physicians with clinically actionable diagnostic information. Its technology platform integrates data comparison and suppression algorithms, learning software, and genetic diagnostics tools and integrated laboratory processes. The company primarily serves hospitals and medical institutions. It markets its tests through internal sales force, as well as through independent sales representatives in the United States, Canada, the People's Republic of China, and internationally. The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. Fulgent Genetics, Inc. was founded in 2011 and is headquartered in Temple City, California.
Receive News & Ratings for Avant Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avant Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.